Loading stock data…
$1.03-0.01 (-1.43%)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States.
NuCana plc in the Healthcare sector is trading at $1.03 with a market capitalization of $5M. The stock is currently near its 52-week low of $0.95, remaining 45.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.44M↑ | -$4.78M↓ | -$2.84M↑ | -$3.57M↑ | -$11.63M |
| Net Income | -$3.08M↑ | -$3.87M↓ | -$2.48M↓ | -$281,000↑ | -$24.11M |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs i...